Researchers at Vanderbilt University, Johns Hopkins University, University of Miami, and The Alfred Hospital studied the lungs of subjects including Veterans using technology developed by 4DMedical ...

I lost my home in the Pacific Palisades fire. Although wildfires have become a part of modern life, you can take steps to ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Quantitative CT is becoming increasingly common for the characterisation of lung disease; however, its added potential as a clinical tool for predicting severe exacerbations remains understudied. We ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...